Cargando…

Dendritic Cell Cancer Therapy: Vaccinating the Right Patient at the Right Time

Immune checkpoint inhibitors propelled the field of oncology with clinical responses in many different tumor types. Superior overall survival over chemotherapy has been reported in various metastatic cancers. Furthermore, prolonged disease-free and overall survival have been reported in the adjuvant...

Descripción completa

Detalles Bibliográficos
Autores principales:	van Willigen, Wouter W., Bloemendal, Martine, Gerritsen, Winald R., Schreibelt, Gerty, de Vries, I. Jolanda M., Bol, Kalijn F.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2018
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6174277/ https://www.ncbi.nlm.nih.gov/pubmed/30327656 http://dx.doi.org/10.3389/fimmu.2018.02265

Ejemplares similares

Response and survival of metastatic melanoma patients treated with immune checkpoint inhibition for recurrent disease on adjuvant dendritic cell vaccination
por: van Willigen, Wouter W., et al.
Publicado: (2020)

Importance of helper T-cell activation in dendritic cell-based anticancer immunotherapy
por: Schreibelt, Gerty, et al.
Publicado: (2013)

Adjuvant dendritic cell vaccination in high-risk uveal melanoma patients
por: Bol, Kalijn, et al.
Publicado: (2015)

Immunological responses to adjuvant vaccination with combined CD1c(+) myeloid and plasmacytoid dendritic cells in stage III melanoma patients
por: Bloemendal, Martine, et al.
Publicado: (2021)

Ipilimumab administered to metastatic melanoma patients who progressed after dendritic cell vaccination
por: Boudewijns, Steve, et al.
Publicado: (2016)

Immune-related Adverse Events of Dendritic Cell Vaccination Correlate With Immunologic and Clinical Outcome in Stage III and IV Melanoma Patients
por: Boudewijns, Steve, et al.
Publicado: (2016)

ASO Author Reflections: Frequent Relapses Prior to the Start of Adjuvant Therapy in Stage IIIB/C Melanoma
por: Bloemendal, Martine, et al.
Publicado: (2019)

Paradigm Shift in Dendritic Cell-Based Immunotherapy: From in vitro Generated Monocyte-Derived DCs to Naturally Circulating DC Subsets
por: Wimmers, Florian, et al.
Publicado: (2014)

Primary Human Blood Dendritic Cells for Cancer Immunotherapy—Tailoring the Immune Response by Dendritic Cell Maturation
por: Sittig, Simone P., et al.
Publicado: (2015)

High Health-Related Quality of Life During Dendritic Cell Vaccination Therapy in Patients With Castration-Resistant Prostate Cancer
por: Westdorp, Harm, et al.
Publicado: (2020)

Naturally circulating dendritic cells to vaccinate cancer patients
por: Bol, Kalijn F., et al.
Publicado: (2013)

Early Recurrence in Completely Resected IIIB and IIIC Melanoma Warrants Restaging Prior to Adjuvant Therapy
por: Bloemendal, Martine, et al.
Publicado: (2019)

The clinical application of cancer immunotherapy based on naturally circulating dendritic cells
por: Bol, Kalijn F., et al.
Publicado: (2019)

Harnessing the cDC1-NK Cross-Talk in the Tumor Microenvironment to Battle Cancer
por: Bödder, Johanna, et al.
Publicado: (2021)

Immune Curbing of Cancer Stem Cells by CTLs Directed to NANOG
por: Wefers, Christina, et al.
Publicado: (2018)

Autologous monocyte-derived DC vaccination combined with cisplatin in stage III and IV melanoma patients: a prospective, randomized phase 2 trial
por: Boudewijns, Steve, et al.
Publicado: (2020)

Reducing cell number improves the homing of dendritic cells to lymph nodes upon intradermal vaccination
por: Aarntzen, Erik HJG, et al.
Publicado: (2013)

Adjuvant dendritic cell vaccination induces tumor-specific immune responses in the majority of stage III melanoma patients
por: Boudewijns, Steve, et al.
Publicado: (2016)

Protamine-stabilized RNA as an ex vivo stimulant of primary human dendritic cell subsets
por: Sköld, Annette E., et al.
Publicado: (2015)

Intranodal vaccination with mRNA-optimized dendritic cells in metastatic melanoma patients
por: Bol, Kalijn F, et al.
Publicado: (2015)

A Comparative Study of the T Cell Stimulatory and Polarizing Capacity of Human Primary Blood Dendritic Cell Subsets
por: Sittig, Simone P., et al.
Publicado: (2016)

Human Dendritic Cell Subset Isolation by Magnetic Bead Sorting: A Protocol to Efficiently Obtain Pure Populations
por: Flórez-Grau, Georgina, et al.
Publicado: (2023)

Trial watch: Dendritic cell (DC)-based immunotherapy for cancer
por: Laureano, Raquel S, et al.
Publicado: (2022)

Monitoring of dynamic changes in Keyhole Limpet Hemocyanin (KLH)-specific B cells in KLH-vaccinated cancer patients
por: Wimmers, Florian, et al.
Publicado: (2017)

Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancer
por: Westdorp, Harm, et al.
Publicado: (2019)

Preclinical exploration of combining plasmacytoid and myeloid dendritic cell vaccination with BRAF inhibition
por: Tel, Jurjen, et al.
Publicado: (2016)

Immunotherapy for Prostate Cancer: Lessons from Responses to Tumor-Associated Antigens
por: Westdorp, Harm, et al.
Publicado: (2014)

In the Right Place, at the Right Time: Spatiotemporal Conditions Determining Plasma Cell Survival and Function
por: Lindquist, Randall L., et al.
Publicado: (2019)

Neoadjuvant immunotherapy for colorectal cancer: Right regimens, right patients, right directions?
por: Zhu, Jiahao, et al.
Publicado: (2023)

Spatial and Temporal Heterogeneity of Tumor-Infiltrating Lymphocytes in Advanced Urothelial Cancer
por: van Wilpe, Sandra, et al.
Publicado: (2022)

The nature of activatory and tolerogenic dendritic cell-derived signal II
por: Bakdash, Ghaith, et al.
Publicado: (2013)

Dendritic Cells Require PINK1-Mediated Phosphorylation of BCKDE1α to Promote Fatty Acid Oxidation for Immune Function
por: Basit, Farhan, et al.
Publicado: (2019)

Prophylactic vaccines are potent activators of monocyte-derived dendritic cells and drive effective anti-tumor responses in melanoma patients at the cost of toxicity
por: Bol, Kalijn F., et al.
Publicado: (2016)

Human Dendritic Cell Subsets Undergo Distinct Metabolic Reprogramming for Immune Response
por: Basit, Farhan, et al.
Publicado: (2018)

The Therapeutic Potential of Tackling Tumor-Induced Dendritic Cell Dysfunction in Colorectal Cancer
por: Subtil, Beatriz, et al.
Publicado: (2021)

T cell landscape within primary melanoma as a biomarker of survival after cancer vaccination in patients with metastatic disease
por: Vasaturo, Angela, et al.
Publicado: (2015)

Functional Contribution and Targeted Migration of Group-2 Innate Lymphoid Cells in Inflammatory Lung Diseases: Being at the Right Place at the Right Time
por: Wirtz, Stefan, et al.
Publicado: (2021)

A Universal Vaccine against Leptospirosis: Are We Going in the Right Direction?
por: Grassmann, André Alex, et al.
Publicado: (2017)

Multiplicity of Mesenchymal Stromal Cells: Finding the Right Route to Therapy
por: Wilson, Alison, et al.
Publicado: (2019)

Naturally produced type I IFNs enhance human myeloid dendritic cell maturation and IL-12p70 production and mediate elevated effector functions in innate and adaptive immune cells
por: Sköld, Annette E., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_qqgh8hppjtbl77i038bpgnhoq7